Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept
(NasdaqGM:KROS),(NYSE:TAK),(TSE:4502.T), LEXINGTON, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ss”) family of proteins, today announced […]